Pharma should be thinking more about the microbiome, as growing evidence reveals its significant impact on drug efficacy, a personalized nutrition expert revealed during NutraIngredients’ 2024 Probiota event.
Targeting gut-derived metabolites with an oral biotherapeutic is effective in improving irritability and anxiety associated with autism spectrum disorder (ASD) according to Axial Therapeutics.
Researchers identified a link between certain metabolites in the blood and perceived satiety after consuming food. The findings could lead to personalized nutrition options that help curb hunger and satiety.
The gut-brain axis plays a key role in the regulation of sugar in the blood. However, those with diabetes experience significantly higher sugar levels because the condition causes the regulation process to malfunction.
The crucial role of microbiota metabolites, and the potential for new technology to create personalised solutions based on scientists understanding of them, has been highlighted by a leading academic from Japan.
